Search





Search





Entrada Therapeutics Inc

TRDA

Add to Watchlist

6.220USD

-0.280-4.31%

Close 09-24 16:00（ET）

241.46MMarket Cap

LossP/E TTM

Entrada Therapeutics Inc

6.220

-0.280-4.31%

Financial Summary Income Statement Balance Sheet Cash Flow Statement Revenue Earnings Company Valuation Risk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial Summary Income Statement Balance Sheet Cash Flow Statement Revenue Earnings Company Valuation Risk Assessment

TRDA Cash Flow Statement

You can access the annual and quarterly cash flow statements of Entrada Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q2

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2020Q4

FY2020Q3

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-10.09%-32.46M

-8.28%-41.70M

-1.89%-32.20M

-16.68%-28.31M

-174.03%-29.49M

-50.90%-38.51M

-687.57%-31.61M

0.92%-24.27M

213.51%39.83M

-112.55%-25.52M

85.30%-4.01M

10.88%-24.49M

-94.85%-35.09M

1068.98%203.40M

-32.92%-27.30M

-95.25%-27.48M

---18.01M

---20.99M

-210.10%-20.54M

-149.34%-14.07M

---6.62M

---5.64M

Net income from continuing operations

0.79%-42.76M

-128.93%-39.72M

-3562.78%-39.16M

-214.52%-44.13M

-178.32%-43.10M

-173.84%-17.35M

111.85%1.13M

-139.57%-14.03M

312.25%55.03M

452.05%23.50M

61.25%-9.54M

241.07%35.46M

-11.86%-25.93M

69.20%-6.67M

-33.51%-24.63M

-74.20%-25.14M

---23.18M

---21.67M

-112.69%-18.45M

-106.44%-14.43M

---8.67M

---6.99M

Operating gains losses

-18.67%841.00K

-14.90%805.00K

-10.69%886.00K

31.27%1.23M

13.63%1.03M

1.28%946.00K

34.78%992.00K

12.35%937.00K

24.66%910.00K

72.64%934.00K

40.19%736.00K

62.26%834.00K

56.65%730.00K

38.72%541.00K

44.23%525.00K

70.20%514.00K

--466.00K

--390.00K

271.43%364.00K

235.56%302.00K

--98.00K

--90.00K

Other non-cash items

53.17%-450.00K

59.04%-548.00K

74.75%-633.00K

77.00%-739.00K

57.50%-961.00K

34.32%-1.34M

-25.41%-2.51M

-73.49%-3.21M

-33.71%-2.26M

-759.49%-2.04M

-1822.12%-2.00M

-5687.50%-1.85M

-1290.85%-1.69M

-266.90%-237.00K

---104.00K

---32.00K

--142.00K

----

Change in working capital

-43.97%4.76M

73.01%-6.98M

106.54%2.35M

179.68%10.21M

145.99%8.49M

49.94%-25.85M

-1316.42%-35.92M

79.44%-12.82M

-63.14%-18.47M

-124.95%-51.65M

149.39%2.95M

-1025.92%-62.33M

-652.24%-11.32M

12676.79%207.01M

-55.82%-5.98M

-716.52%-5.54M

--2.05M

---1.65M

-308.53%-3.84M

-157.46%-678.00K

--1.84M

--1.18M

-Change in receivables

-103.36%-29.00K

-76.16%390.00K

101.76%19.00K

-100.32%-16.00K

-98.76%864.00K

102.28%1.64M

-26.26%-1.08M

495.86%5.07M

2635.61%69.84M

-1037.62%-71.64M

---853.00K

---1.28M

--2.55M

---6.30M

----

-Change in prepaid expenses

-50.92%2.30M

-8.27%-2.46M

150.59%1.50M

393.32%3.73M

262.95%4.68M

-184.81%-2.27M

-123.75%-2.97M

91.39%-1.27M

-143.88%-2.87M

-38.23%2.68M

725.17%12.52M

-55.36%-14.78M

881.03%6.54M

359.82%4.34M

68.14%-2.00M

-1332.53%-9.51M

---838.00K

---1.67M

-494.97%-6.28M

-224.34%-664.00K

--1.59M

--534.00K

-Change in other current assets

-39.29%1.69M

-38.99%1.67M

-43.37%1.76M

37.53%3.60M

-39.35%2.78M

7.11%2.74M

201.26%3.12M

43.47%2.61M

59.77%4.59M

148.29%2.56M

146.70%1.03M

-6.23%1.82M

11.97%2.87M

-619.71%-5.30M

-239.07%-2.21M

200.31%1.94M

--2.56M

--1.02M

52966.67%1.59M

-2880.00%-1.94M

--3.00K

---65.00K

-Change in other current liabilities

89.48%-81.00K

99.52%-88.00K

99.64%-122.00K

97.53%-419.00K

99.12%-770.00K

-203.46%-18.51M

-77.73%-33.72M

55.60%-16.97M

-503.22%-87.02M

-91.54%17.89M

---18.97M

---38.21M

---14.43M

--211.58M

-100.00%0.00

----

--0.00

272.73%57.00K

-1485.71%-222.00K

---33.00K

---14.00K

Cash from non-recurring investing activities

Cash from operating activities

-10.09%-32.46M

-8.28%-41.70M

-1.89%-32.20M

-16.68%-28.31M

-174.03%-29.49M

-50.90%-38.51M

-687.57%-31.61M

0.92%-24.27M

213.51%39.83M

-112.55%-25.52M

85.30%-4.01M

10.88%-24.49M

-94.85%-35.09M

1068.98%203.40M

-32.92%-27.30M

-95.25%-27.48M

---18.01M

---20.99M

-210.10%-20.54M

-149.34%-14.07M

---6.62M

---5.64M

Investing cash flow

Net cash from continuing investing activities

-96.00%11.00K

-96.15%44.00K

-132.60%-207.00K

-126.76%-171.00K

-73.71%275.00K

36.52%1.14M

-34.94%635.00K

-55.87%639.00K

-31.27%1.05M

-49.76%838.00K

37.85%976.00K

78.77%1.45M

96.39%1.52M

180.81%1.67M

-46.44%708.00K

0.50%810.00K

--775.00K

--594.00K

-8.89%1.32M

240.08%806.00K

--1.45M

--237.00K

Capital expenditures

-96.00%11.00K

-96.15%44.00K

----

-73.71%275.00K

36.52%1.14M

-34.94%635.00K

-55.87%639.00K

-31.27%1.05M

-49.76%838.00K

37.85%976.00K

78.77%1.45M

96.39%1.52M

180.81%1.67M

-46.44%708.00K

0.50%810.00K

--775.00K

--594.00K

-8.89%1.32M

240.08%806.00K

--1.45M

--237.00K

Net cash flow from disposal of fixed assets

-96.00%11.00K

-96.15%44.00K

-132.60%-207.00K

-126.76%-171.00K

-73.71%275.00K

36.52%1.14M

-34.94%635.00K

-55.87%639.00K

-31.27%1.05M

-49.76%838.00K

37.85%976.00K

78.77%1.45M

96.39%1.52M

180.81%1.67M

-46.44%708.00K

0.50%810.00K

--775.00K

--594.00K

-8.89%1.32M

240.08%806.00K

--1.45M

--237.00K

Net cash flow from investment products

61.31%54.96M

356.07%27.03M

-46.46%28.91M

159.47%48.94M

246.00%34.07M

-78.04%5.93M

169.74%54.00M

-3494.93%-82.29M

79.11%-23.34M

169.59%26.98M

2.66%20.02M

75.45%-2.29M

-546.94%-111.73M

78.57%-38.78M

--19.50M

---9.32M

--25.00M

---180.94M

----

Net cash flow from other investing activities

--0.00

----

Cash from non-current investing activities

Net cash flow from investing activities

62.59%54.95M

464.23%26.99M

-45.43%29.12M

159.22%49.11M

238.61%33.80M

-81.71%4.78M

180.23%53.37M

-2119.08%-82.93M

78.47%-24.38M

164.65%26.15M

1.34%19.04M

63.12%-3.74M

-567.52%-113.26M

77.72%-40.44M

1521.48%18.79M

-1157.32%-10.13M

--24.23M

---181.53M

8.89%-1.32M

-240.08%-806.00K

---1.45M

---237.00K

Financing cash flow

Cash flow from continuous financing activities

3.86%350.00K

-71.43%100.00K

-86.31%192.00K

172.73%8.00K

-99.67%337.00K

69.90%350.00K

103.19%1.40M

-102.99%-11.00K

22781.94%101.37M

-98.95%206.00K

92.74%690.00K

513.33%368.00K

3927.27%443.00K

38972.00%19.54M

-99.81%358.00K

-43.40%60.00K

--11.00K

--50.00K

127923.49%190.75M

-99.57%106.00K

--149.00K

--24.86M

Net cash flow from common stock issuance/repurchase

0.95%320.00K

----

-53.38%145.00K

100.00%0.00

-99.68%317.00K

----

-54.93%311.00K

-206.52%-392.00K

22532.73%100.26M

-100.00%0.00

142.96%690.00K

--368.00K

--443.00K

--19.54M

-99.85%284.00K

----

--190.69M

----

Net cash flow from preferred stock issuance/repurchase

----

--0.00

-100.00%0.00

--0.00

--24.86M

Proceeds from stock option exercised by employees

50.00%30.00K

-71.43%100.00K

-95.69%47.00K

-97.90%8.00K

-98.19%20.00K

69.90%350.00K

--1.09M

--381.00K

--1.10M

--206.00K

----

15.63%74.00K

-43.40%60.00K

--11.00K

--50.00K

-57.05%64.00K

--106.00K

--149.00K

--0.00

Net cash flow from other financing activities

--320.00K

--0.00

----

Net cash from non-recurrent financing activities

Net cash from financing activities

3.86%350.00K

-71.43%100.00K

-86.31%192.00K

172.73%8.00K

-99.67%337.00K

69.90%350.00K

103.19%1.40M

-102.99%-11.00K

22781.94%101.37M

-98.95%206.00K

92.74%690.00K

513.33%368.00K

3927.27%443.00K

38972.00%19.54M

-99.81%358.00K

-43.40%60.00K

--11.00K

--50.00K

127923.49%190.75M

-99.57%106.00K

--149.00K

--24.86M

Net cash flow

Beginning cash balance

11.07%79.74M

-10.29%94.34M

18.58%97.24M

-59.60%76.43M

-0.83%71.79M

46.97%105.16M

46.87%82.00M

126.07%189.20M

-68.74%72.39M

45.71%71.55M

-2.50%55.83M

-11.73%83.69M

161.43%231.60M

-83.13%49.11M

-53.13%57.26M

-30.76%94.82M

--88.59M

--291.06M

160.10%122.17M

389.29%136.95M

--46.97M

--27.99M

Current period cash flow changes

391.63%22.84M

56.23%-14.61M

-112.49%-2.89M

119.41%20.80M

-96.02%4.64M

-4101.68%-33.37M

47.34%23.16M

-284.78%-107.20M

178.98%116.82M

-99.54%834.00K

292.79%15.72M

25.81%-27.86M

-2475.22%-147.91M

190.13%182.49M

-104.83%-8.15M

-154.19%-37.56M

--6.23M

---202.47M

2230.86%168.89M

-177.84%-14.78M

---7.93M

--18.98M

Ending cash balance

34.20%102.57M

11.07%79.74M

-10.29%94.34M

18.58%97.24M

-59.60%76.43M

-0.83%71.79M

46.97%105.16M

46.87%82.00M

126.07%189.20M

-68.74%72.39M

45.71%71.55M

-2.50%55.83M

-11.73%83.69M

161.43%231.60M

-83.13%49.11M

-53.13%57.26M

--94.82M

--88.59M

645.46%291.06M

160.10%122.17M

--39.05M

--46.97M

Free cash flow

-9.10%-32.47M

-5.27%-41.74M

0.11%-32.20M

-13.68%-28.31M

-176.74%-29.76M

-50.44%-39.65M

-546.22%-32.24M

3.99%-24.91M

205.94%38.79M

-113.07%-26.36M

82.19%-4.99M

8.31%-25.94M

-94.92%-36.61M

1034.59%201.73M

-28.13%-28.01M

-90.12%-28.29M

---18.78M

---21.59M

-170.75%-21.86M

-152.99%-14.88M

---8.07M

---5.88M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Entrada Therapeutics Inc Generate?



Entrada Therapeutics Inc generated -128.51M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Entrada Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Entrada Therapeutics Inc's operating cash flow increased by -209.24% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Entrada Therapeutics Inc Spend on Capital Expenditures?



Entrada Therapeutics Inc spent 1.04M on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Entrada Therapeutics Inc's Financing Cash Flow Changed?



Entrada Therapeutics Inc used 887.00K in financing activities in the latest quarter.

What is free cash flow and why does it matter for TRDA?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Entrada Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -129.55M reflecting a -189.73% change from the previous year.